Abstract
Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.
| Original language | English |
|---|---|
| Pages (from-to) | 306-310 |
| Number of pages | 5 |
| Journal | Circulation Journal |
| Volume | 69 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2005 Mar 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Angioplasty
- Nicorandil
- Percutaneous coronary intervention
- Unstable angina
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. / Ju, Han Kim; Myung, Ho Jeong; Kyung, Ho Yun; Kye, Hun Kim; Dong, Koo Kang; Seo, Na Hong; Lim, Sang Yeob; Sang, Hyun Lee; Yun, Sang Lee; Young, Joon Hong; Hyung, Wook Park; Kim, Weon; Young, Keun Ahn; Jeong, Gwang Cho; Jong, Chun Park; Jung, Chaee Kang.
In: Circulation Journal, Vol. 69, No. 3, 01.03.2005, p. 306-310.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina
AU - Ju, Han Kim
AU - Myung, Ho Jeong
AU - Kyung, Ho Yun
AU - Kye, Hun Kim
AU - Dong, Koo Kang
AU - Seo, Na Hong
AU - Lim, Sang Yeob
AU - Sang, Hyun Lee
AU - Yun, Sang Lee
AU - Young, Joon Hong
AU - Hyung, Wook Park
AU - Kim, Weon
AU - Young, Keun Ahn
AU - Jeong, Gwang Cho
AU - Jong, Chun Park
AU - Jung, Chaee Kang
PY - 2005/3/1
Y1 - 2005/3/1
N2 - Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.
AB - Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.
KW - Angioplasty
KW - Nicorandil
KW - Percutaneous coronary intervention
KW - Unstable angina
UR - http://www.scopus.com/inward/record.url?scp=20144377820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20144377820&partnerID=8YFLogxK
U2 - 10.1253/circj.69.306
DO - 10.1253/circj.69.306
M3 - Article
C2 - 15731536
AN - SCOPUS:20144377820
VL - 69
SP - 306
EP - 310
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 3
ER -